Risk of proton pump inhibitors treatment in relationship to SARS-CoV-2 disease

Czech version

Authors: Peter Vaňuga ¹; Juraj Payer ²; Milan Kriška ³; František Sándor ⁴; Andrej Dukát ²
Authors‘ workplace: Národný endokrinologický a diabetologický ústav, n. o., Ľubochňa ¹; V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava ²; Ústav farmakológie a klinickej farmakológie LF UK v Bratislave ³; Klinika pneumológie a ftizeológie LF UK a UNB, Nemocnica Ružinov, Bratislava ⁴
Published in: Forum Diab 2022; 11(1): 39-42
Category:

Overview

Medicína v dobe pandémie SARS-CoV-2 našu klinickú prax postavila pred celkom nové problémy. Jedným z nich predstavujú aj riziká pre toto infekčné ochoreníe. Okrem všeobecne známych rizík, ako je vek a komorbidity, sa ukázala byť dôležitá aj trvajúca zavedená liečba pacientov. V tomto kontexte je potrebné sa zamerať na jednu skupinu liekov vo farmakoterapii – PPI, nakoľko sa jedná o veľmi častú liečbu v klinickej praxi všade vo svete. Diskusie o tejto liečbe sa s poznatkami vyvíjajú a stále pokračujú.

Keywords:

PPI – therapy – SARS-CoV-2

Sources

1. Almano CHV, Chey WD, Spiegel MBR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. Am J Gastroenterol 2020; 115(10): 1707–1715. Dostupné z DOI: <http://dx.doi.org/10.14309/ajg.0000000000000798>
.2. Marks D. Time to halt the overprescribing of proton pump inhibitors. Clin Pharm 2016; 8(8). Dostupné z DOI: <http://dx.doi.org/doi.org/10.1211/CP.2016.20201548>.
3. Martinsen TC, Fossmark R, Waldum HL. The phylogeny and biological function of gastric juice-microbiological cosequences of removing gastric acid. Int J Mol Sci 2019; 20(23): 6031. Dostupné z DOI: <http://dx.doi.org/doi.org/10.3390/ijms.20236031>.
4. Vilcu AM, Sabatte L, Blanchon T et al. Association between acute gastroenteritis and continuous use of proton pump inhibitors during winter periods of highest circulation of enteric viruses. JAMA Netw Open 2019; 2(11): e1916205. <http://dx.doi.org/10.1001/jamanetworkopen.2019.16205>.
5. Xiao F, Tamg M, Zheng X ei al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020: 158(6): 1831–1833. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2020.02.055>.
6. Zhang H, Liao YS, Gong J et al. Clinical characteristics of coronavirus disease (COVID-19) patients with gastrointestinal symptoms: a report of 164 cases. Dig Liver Dis 2020; 52(10): 1076–1079. Dostupné z DOI: <http://dx.doi.org/doi.org/10.1016/j.dld.2020.04.034>.
7. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497–506. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(20)30183–5>.
8. Luxenburger H, Sturm L, Biever P et al. Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor? J Intern Med 2021; 289(1): 121–124. Dostupné z DOI: <http://dx.doi.org/10.1111/joim.13121>.
9. Eom CS, Jeon CY, Lim JW et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183(3): 310–319. Dostupné z DOI: <http://dx.doi.org/10.1503/cmaj.092129>.
10. Charpiat B, Bleyzac N, Tod M. Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19? Clin Drug Invest 2020; 40(10): 897–899. Dostupné z DOI: <http://dx.doi.org/10.1007/s40261–020–00963-x>.
11. Chen X, Liao B, Cheng L et al. The microbial coinfection in COVID-19. Appl Microbiol Biotechnol 2020; 104/18): 7777–7785. Dostupné z DOI: <http://dx.doi.org/10.1007/s00253–020–10814–6>.
12. Lim YK, Kweon OJ, Kim HR et al. Impact of bacterial and viral coinfection in community-acquired pneumonia in adults. Diagn Microbiol Infect Dis 2019; 94(1): 1: 50–54. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diagmicrobio.2018.11.014>.
13. Martins-Filho PR, Tavares CSS, Santos VS. Factors associated with mortality in patients with COVID-19. Eur J Intern Med 2020; 76: 97–99. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejim.2020.04.043>.
14. Dukát A, Kubíková E, Payer J, Šimko F. Aké sú možné úlohy črevného mikrobiómu v procese vývoja endotelovej dysfunkcie a následnej aterosklerózy? Int Med 2018; 18(9): 383–385.
15. Homolak J, Kodvanj I, Trkulja V. An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19. Clin Drug Invest 2021; 41(3): 287–289. Dostupné z DOI: <http://dx.doi.org/10.1007/s40261–021–01007–8>.
16. Lee SW, Ha EK, Yeniova AO et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut 2021; 70(1): 76–84. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2020.322248>.
17. Toubasi AA, AbuAzenh RB, Khraisat BR et al. Proton Pump Inhibitors: Current Use and the Risk of Coronavirus Infectious Disease 2019 Development and its Related Mortality. Meta-analysis. Arch Med Res 2021; 52(6): 656–659. Dostupné z DOI: <http://dx.doi.org/10.1016/j.arcmed.2021.03.004>.
18. Li GF, An XX, Yu Y et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. BMJ Gut 2021; 70(9): 1806–1808. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2020–323366>.
19. Yang M, He Q, Gao F et al. Regular use of proton-pump inhibitors and risk of stroke: a population-based cohort study and meta-analysis of randomized-controlled trials. BMC Medicine 2021: 19(1): 316. Dostupné z DOI: <http://doi.org/10.1186/s12916–021–02189–5>.
20. Lim YK, Kweon OJ, Kim HR et al. Impact of bacterial and viral coinfection in community-acquired pneumonia in adults. Diagn Microbiol Infect Dis 2019; 94(1):50–54. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diagmicrobio.2018.11.014>.
21. Xiao F, Tamg M, Zheng X et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020; 158(6): 1831–1833. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2020.02.055>.
22. Prag C, Prag M, Fredlund H. Proton pump inhibitors as a risk factor for norovirus infection. Epidemiol Infect 2017; 145(8): 1617–1623. Dostupné z DOI: <http://dx.doi.org/10.1017/S0950268817000528>.
23. Kow CHB, Hasan SS. Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis. J Int Med 2021; 289(1): 125–128. Dostupné z DOI: <http://dx.doi.org/10.1111/joim.13183>.